The FDA put 4D Molecular Therapeutics’ gene therapy program, 4D-310, on clinical hold, the company announced February 2.
Tag Archive for: Entrada Therapeutics
Entrada Therapeutics said it received a clinical hold notice from the regulatory agency but no reason was provided. “We are eager to resolve this hold and continue down the treatment development pathway,” President and CEO Dipal Doshi said.
Vertex Pharmaceuticals agreed to a collaboration deal with the pre-clinical biotech Entrada Therapeutics, Thursday. The two companies announced a global partnership to develop intracellular Endosomal Escape Vehicle (EEV) therapeutics.
